Across TCGA pan-cancer cohorts, RNF220 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RNF220 data layer compared with 30 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RNF220 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RNF220 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and COAD are the cancer types where RNF220 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.169	0.710	.008	18	view →
UCEC	DFS	Median	III,IV	1.000	0.525	.010	16	view →
COAD	OS	Median	III,IV	0.233	0.798	.001	15	view →
ESCA	OS	Median	All	0.095	0.701	<.001	12	view →
SCLC	OS	Median	All	0.274	0.711	.008	9	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RNF220 tumor-vs-normal RNA expression · all RNF220 data types